Table 2.

CLSI and FDA breakpoints for Acinetobacter spp

Antibiotic	Susceptible breakpoints (µg/mL)		FDA cleared cAST
	CLSI	FDA
Ampicillin-sulbactam	≤8/4	≤8a	All automated systems, Etest and disk
Piperacillin-tazobactam	≤16/4	≤16/4b	All automated systems, Etest and disk
Ceftazidime	≤8	None
Cefepime	≤8	None
Cefotaxime	≤8	≤8
Ceftriaxone	≤8	None
Doripenem	≤2	≤1
Imipenem	≤2	≤4	All automated systems, Etest and disk
Meropenem	≤2	None
Polymyxin B	≤2	None	None
Colistin	≤2	None	None
Gentamicin	≤4	None
Tobramycin	≤4	None
Amikacin	≤16	≤16
Doxycycline	≤4	≤4
Minocycline	≤4	≤4	Etest and disk
Tetracycline	≤4	≤4
Ciprofloxacin	≤1	None
Levofloxacin	≤2	None
Trimethoprim-sulfamethoxazole	≤2/38	None
Tigecyclinec	None	None	None

^aFor Acinetobacter calcoaceticus only

^bFor A. baumannii only

^cMany use a functional breakpoint of ≤2 ug/mL, but this has not been clinically validated